Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

BioCryst identifies development candidate in complement inhibitor program

Aug. 28, 1998

Preclinical and clinical data reported for orbofiban, a potent antiplatelet agent

Aug. 28, 1998

AR-C69931MX; a novel P2T antagonist with platelet aggregation-inhibitory activity

Aug. 28, 1998

ACS news flash: R.W. Johnson investigates thrombin inhibitors

Aug. 25, 1998

Eptifibatide treatment reduces incidence of death in acute myocardial infarction and unstable angina

Aug. 25, 1998

Corvas and Schering-Plough discontinue collaboration; other projects remain on track

Aug. 24, 1998

Novel antithrombotic agents added to the pipeline at NicOx

Aug. 17, 1998

Zeneca claims factor Xa inhibitors with antithrombotic/anticoagulant activity

Aug. 17, 1998

First volunteers dosed with R.W. Johnson's new gpIIb/IIIa antagonist

Aug. 14, 1998

NQ-304, a novel platelet antiaggregatory and antithrombotic agent in early development

Aug. 12, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 26, 2025.
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 26, 2025
Roche looks to grow with sequencing by expansion tech
BioWorld MedTech
Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...
Clots and metastasis in cancer patients start in the lung
BioWorld MedTech
The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by Cornell University scientists. In the...